Meeting
2021 ASCO Annual Meeting
Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.
Authors
Yufei Liu
The University of Texas MD Anderson Cancer Center, Houston, TX
Yufei Liu , Zhe Zhang , Waree Rinsurongkawong , Xiuning Le , Carl Michael Gay , Matthew S. Ning , John Heymach , Jianjun Zhang , Steven H. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8528)
DOI
10.1200/JCO.2021.39.15_suppl.8528
Abstract #
8528
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2023 ASCO Annual Meeting
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
First Author: Jeffrey A. Scott